|Description||PPPA is a competitive NMDA receptor antagonist that displays moderate selectivity for NR2A-containing receptors (Ki=0.13, 0.47, 1.10 and 3.86 μM for GluN2A, GluN2B, GluN2C and GluN2D subunits respectively). Some findings support the hypothesis that PPPA and reward synergize to enhance initiate dopamine (DA) excitation.|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
Amantadine is can be used as an antiviral and an antiparkinsonian drug. It is a NMDA receptor antagonist. Amantadine is also a useful building block in organic ...
ZD 9379 is an antagonist of glycine site on the NMDA receptor, displaying neuroprotective effects. ZD 9379 reduces infarct size and frequency of spreading depre...
cis-ACPD has been found to be a potent NMDA receptor agonist as well as a mGluR agonist.
GV-196771, an indole derivative, has been found to be a non-opioid analgesic agent which is also a NMDA antagonist binds to glycine-binding site and was once st...
Traxoprodil mesylate is a NR2B selective antagonist of NMDA glutamate receptors.
DNQX disodium salt
The sodium salt form of DNQX, which is a selective non-NMDA receptor antagonist and could probably be useful in the treatment of Alzheimer's disease.
(R)-3-Carboxy-4-hydroxyphenylglycine has been found to be an antagonist of NMDA and AMPA/kainate receptor.
Rapastinel, a brain penetrable tetrapeptide, could be a partial agonist of NMDA receptor. It was already finished the Phase II trial for acting as an antidepres...